Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Anebulo Pharmaceuticals, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 40.78M shares outstanding
USAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction.
Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
The company was incorporated in 2020 and is based in Lakeway, Texas.
Leadership
Areta Kupchyk
Ms.
Aron R. English
Director
Bimal Shah
Member of the Board
Jason M. Aryeh
Member of the Board
Employees
2
Country
US
Sector
Healthcare
Website
anebulo.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Calloway Nathaniel | Director | Grant/Award | 3.3K | -- | Apr 4, 2025 |
 Lawler Joseph F. | Director | Grant/Award | 25.0K | -- | Apr 4, 2025 |
| Lawler Joseph F. | Director | Grant/Award | 13.2K | -- | Apr 4, 2025 |
 SHAH BIMAL R. | Director | Grant/Award | 25.0K | -- | Apr 4, 2025 |
| SHAH BIMAL R. | Director | Grant/Award | 6.6K | -- | Apr 4, 2025 |
 Cundy Kenneth C | Chief Scientific Officer | Grant/Award | 115.0K | -- | Apr 4, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Aron R. English · may incl. warrants· filed Feb 2025 | 21.9M | 53.8% | 13D |
Nantahala Capital Management, LLC · filed Feb 2026 | 3.5M | 8.7% | 13G |
Mangrove Partners IM, LLC · filed Mar 2025 | 2.5M | 6.2% | 13G |
VANGUARD GROUP INC | 435.8K | 1.1% | 13F |
Insiders
- Calloway NathanielDirector
- Lawler Joseph F.Director
- SHAH BIMAL R.Director
- Cundy Kenneth CChief Scientific Officer
- Aryeh JasonDirector
- Cunningham, Richard AnthonyChief Executive Officer
- Lin KennethDirector
- Kupchyk AretaDirector
- English Aron R.Director
Top institutional holders
based on 40.78M shares outstanding
US30d Avg
179
60d Avg
211
90d Avg
211